APA (7th ed.) Citation

Lampson, B. L., Kasar, S. N., Matos, T. R., Morgan, E. A., Rassenti, L., Davids, M. S., . . . Brown, J. R. (2016). Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood, 128(2), 195-203. https://doi.org/10.1182/blood-2016-03-707133

Chicago Style (17th ed.) Citation

Lampson, Benjamin L., et al. "Idelalisib Given Front-line for Treatment of Chronic Lymphocytic Leukemia Causes Frequent Immune-mediated Hepatotoxicity." Blood 128, no. 2 (2016): 195-203. https://doi.org/10.1182/blood-2016-03-707133.

MLA (9th ed.) Citation

Lampson, Benjamin L., et al. "Idelalisib Given Front-line for Treatment of Chronic Lymphocytic Leukemia Causes Frequent Immune-mediated Hepatotoxicity." Blood, vol. 128, no. 2, 2016, pp. 195-203, https://doi.org/10.1182/blood-2016-03-707133.